According to a recent LinkedIn post from SpinaFX Medical Inc, the company drew strong interest in a workshop it held at the ASSR 2026 meeting in New Orleans focused on image‑guided intra‑discal oxygen ozone injection for contained herniated discs. The session reportedly covered hands‑on C‑arm guided needle placement, clinical evidence, patient selection, and follow‑up, along with discussion of SpinaFX’s planned pivotal clinical trial.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post highlights engagement from key interventional and radiology specialists, which may signal growing clinical awareness and potential early adopter interest in the company’s minimally invasive back‑pain treatment approach. If the planned pivotal trial proceeds and yields favorable data, it could support future regulatory milestones and reimbursement discussions, potentially strengthening SpinaFX’s positioning within the spine and image‑guided therapy medtech segment.
Increased visibility at a specialty conference such as ASSR may also help SpinaFX build relationships with opinion leaders who can influence procedure adoption and guideline inclusion over time. For investors, the activity suggests the company is moving from educational groundwork toward clinical validation, a step that may be important for future fundraising, strategic partnerships, or eventual commercialization efforts around its breakthrough‑device strategy.